Inventiva (IVA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Inventiva is gearing up for its Combined General Meeting on December 11, 2024, where shareholders will vote on crucial resolutions, including a financing plan of up to 348 million euros and the appointment of new directors. The biopharmaceutical company, known for its work on MASH/NASH treatments, is advancing its clinical pipeline, with lanifibranor in a Phase 3 trial and plans for further development activities. This meeting marks a significant step for Inventiva as it navigates its strategic and financial future.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
